Management of Checkpoint Inhibitor‑Induced Cardiotoxicity

Immediate Management

• Discontinue checkpoint‑inhibitor therapy permanently for any grade of cardiac toxicity, including grade 1, and hold the drug immediately upon suspicion of cardiotoxicity. This rapid cessation is recommended by the oncology consensus and is supported by multiple clinical observations. 1
• Admit the patient urgently and obtain cardiology consultation; transfer to a coronary‑care unit when troponin is elevated or new conduction abnormalities are present. Early specialist involvement and intensive monitoring are emphasized to mitigate rapid deterioration. 1
• Start high‑dose corticosteroids (prednisone or equivalent 1–2 mg/kg/day, oral or IV according to severity) as soon as possible; for grade 2 or higher, initiate within 24 hours. Early steroid therapy has been shown to be beneficial without added adverse effects. 2
• Continue corticosteroids until clinical symptoms resolve and cardiac biomarkers (troponin), left‑ventricular systolic function, and conduction abnormalities have normalized. This duration ensures complete suppression of immune‑mediated injury. 3

Diagnostic Work‑up

• Electrocardiogram (ECG) to identify QTc prolongation, new conduction disease, ST‑T changes, or arrhythmias. ECG is the first‑line tool for detecting electrical disturbances. 3
• Serial cardiac troponin measurement (prefer troponin I when skeletal‑muscle disease is present). Elevated troponin is a sensitive marker of myocardial injury in this setting. 3
• BNP or NT‑pro‑BNP testing; values > 500 pg/mL signal significant cardiac stress. Natriuretic peptides help gauge the severity of myocardial involvement. 1
• Transthoracic echocardiography with global longitudinal strain assessment. Strain imaging improves early detection of subtle systolic dysfunction. 3
• Chest radiography to evaluate pulmonary congestion or other thoracic pathology. Plain film assists in rapid bedside assessment. 1
• Cardiac magnetic resonance imaging (CMR) when myocarditis is suspected, troponin is elevated, or ECG is abnormal. CMR provides tissue characterization and confirms inflammatory injury. 3
• Endomyocardial biopsy if clinical suspicion remains high despite non‑invasive work‑up. Biopsy offers definitive histologic diagnosis when needed. 3
• Additional labs: C‑reactive protein and viral serologies to exclude alternative etiologies; repeat troponin at 6 hours if initially elevated. Comprehensive testing ensures accurate attribution to immune‑related injury. 2

Escalation for Steroid‑Refractory Cases

• Administer “cardiac‑transplant rejection” dose methylprednisolone 1 g daily when standard high‑dose steroids fail to produce a response. Pulse steroids are recommended for rapid immunosuppression. 4
• Add a second‑line immunosuppressant such as mycophenolate, infliximab, or antithymocyte globulin (ATG). Combination therapy is advised for refractory inflammation. 4
• Consider abatacept (CTLA‑4‑Ig) or alemtuzumab (anti‑CD52) in life‑threatening cases. These agents target additional immune pathways when conventional agents are insufficient. 2
• Avoid high‑dose infliximab (> 5 mg/kg) in patients with moderate‑to‑severe heart failure, as it is contraindicated. Safety data highlight the risk of worsening cardiac function. 1

Standard Cardiac Care (ACC/AHA Guidelines)

• Manage all cardiac manifestations according to American College of Cardiology/American Heart Association (ACC/AHA) guidelines, with cardiology oversight. Guideline‑directed therapy ensures evidence‑based treatment of heart failure, arrhythmias, and other complications. 1
• Provide guideline‑directed medical therapy for cardiomyopathy or heart failure (e.g., ACE inhibitors, beta‑blockers) as indicated. Standard heart‑failure drugs are incorporated once immune‑mediated injury is controlled. 3
• Treat atrial or ventricular tachyarrhythmias and heart block per ACC/AHA recommendations; consider pacemaker implantation for new conduction delays. Device therapy follows established electrophysiology protocols. 2
• Escalate to respiratory and hemodynamic support (including mechanical ventilation and vasopressors) for severe or fulminant presentations. Intensive care measures are essential for patients with cardiogenic shock. 5

Special Considerations

• Triple‑M syndrome (myositis, myasthenia gravis, myocarditis) may occur, often heralded by markedly elevated troponin. Clinicians should remain vigilant for neuromuscular signs that may accompany cardiac toxicity. 2
• Incidence of cardiovascular immune‑related adverse events is < 0.1 % among checkpoint‑inhibitor recipients; risk rises to 0.28 % with combination ipilimumab + nivolumab versus 0.06 % with nivolumab alone. These epidemiologic data underscore the rarity but heightened risk with combination regimens. 4

Evidence Strength

• The above recommendations are primarily based on anecdotal evidence, case reports, and small case series (Level C‑LD, low certainty), reflecting the rarity of these events and the limited high‑quality data available. 1

Cardiac Involvement in Myositis

Introduction to Cardiac Complications

• Cardiac involvement in myositis is a potentially fatal complication that demands systematic cardiac screening in every patient with suspected or confirmed myositis, as myocarditis significantly increases mortality risk (approximately 20% vs <10% in idiopathic inflammatory myositis without cardiac involvement) 6

Clinical Presentation and Screening

• Myocarditis frequently co-occurs with immune-related myositis and represents the primary driver of mortality in these patients 6
• Normal cardiac enzymes cannot always rule out myocarditis, making comprehensive cardiac evaluation essential even when initial biomarkers appear reassuring 6
• Myositis with cardiac involvement typically occurs early after immune checkpoint inhibitor initiation (median 25 days, IQR 25-45 days) 6
• Life-threatening manifestations include dyspnea, palpitations, chest pain, or syncope—any of these symptoms should immediately trigger suspicion for concurrent myocarditis 6

Systematic Cardiac Evaluation

• Every patient with myositis or suspected myositis must undergo cardiac troponin (troponin I is more specific than troponin T when skeletal muscle disease is present) 6
• Electrocardiography to detect QTc prolongation, new conduction disease, or ST-T wave changes 7, 8, 9, 10, 11
• BNP measurement (levels >500 pg/ml indicate significant concern) 7, 8, 9, 10, 11

Advanced Imaging and Monitoring

• Cardiac MRI is necessary if clinical syndrome suggests myocarditis, cardiac troponin is elevated, or ECG shows abnormalities 6
• Baseline ECG and cardiac biomarker assessment should be established before therapy to identify notable changes during treatment 7, 8, 9, 10, 11

Clinical Red Flags and Laboratory Markers

• Bulbar symptoms (dysphagia, dysarthria, dysphonia) or respiratory failure may indicate myositis severity or associated myasthenia gravis (present in 12.5% of cases) 6
• Ptosis and diplopia commonly signal associated myasthenia gravis 6
• Dropped head syndrome can occur 6
• Creatine kinase (CK) elevation is seen in the majority of myositis patients (median 2650 IU/L, range 335-20,270 IU/L) 6
• CK levels are typically normal in patients with myalgia alone, helping distinguish true myositis from muscle pain 6
• Transaminases (AST, ALT), LDH, and aldolase may also be elevated 12

Treatment Implications

• Patients with confirmed myocarditis (or reasonable suspicion) should receive emergent high-dose corticosteroids 7, 8, 9, 10, 11
• Permanently discontinue immune checkpoint inhibitors in grade 4 (life-threatening) cases 7, 8, 9, 10, 11
• High-dose corticosteroids: 1 mg/kg methylprednisolone IV for at least several days until improved to grade ≤1, followed by at least 4-5 weeks of tapering doses 7, 8, 9, 10, 11
• Consider withholding immune checkpoint inhibitors in grade 3 (moderate abnormalities) cases 7, 8, 9, 10, 11
• Hold therapy until stabilized if confirmed cardiac injury or decompensation 7, 8, 9, 10, 11
• Consider corticosteroids if myocarditis is suspected 7, 8, 9, 10, 11

Myositis Without Cardiac Involvement

• Hold immune checkpoint inhibitors until Grade 1 or less while off immune suppression in severe myositis (Grade 3-4) without cardiac involvement 12
• Initiate prednisone 1 mg/kg or equivalent 12
• Consider 1-2 mg/kg methylprednisolone IV or higher-dose bolus if severe compromise exists (weakness severely limiting mobility, respiratory compromise, dysphagia) 12
• Consider plasmapheresis or IVIG therapy 12
• Approximately 10% of patients receive plasma exchanges, and up to 20% receive intravenous immunoglobulins 6

Critical Consultation Requirement

• Active, ongoing consultation with a cardiologist to discuss the risk/benefit of continuing immune checkpoint inhibitor therapy, starting corticosteroids, or instituting other cardiac treatments cannot be overstated 7, 8, 9, 10, 11